Related Experiment Video
Updated: Jun 19, 2026
06:08
Formulating and Characterizing an Exosome-based Dopamine Carrier System
Published on: April 4, 2022
Engineering Nanocarriers for Dopamine Stabilization and Targeted Brain Delivery: Mechanisms, Approaches and
Sandip Patra1,2, Aakash Nathani3
1Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.
International Journal of Nanomedicine
|June 18, 2026
Summary
Nanomedicine offers a promising solution for delivering dopamine to the brain, overcoming limitations of conventional therapies for neurological disorders like Parkinson's disease. These advanced systems enhance dopamine stability and targeted delivery, improving treatment efficacy.
Area of Science:
- Neuroscience and Pharmacology
- Nanotechnology and Drug Delivery
Background:
- Dopamine is crucial for motor control and cognition, but its dysregulation is linked to Parkinson's disease.
- Conventional dopamine therapies face challenges including poor blood-brain barrier (BBB) penetration and rapid metabolism.
Purpose of the Study:
- To review current advancements in nanomedicine strategies for dopamine delivery to the brain.
- To highlight nanocarriers' potential in enhancing dopamine stability and protecting against oxidative stress.
Main Methods:
- Comprehensive literature review of nanomedicine-based dopamine delivery systems.
- Analysis of various nanocarrier platforms: polymeric nanoparticles, liposomes, dendrimers, inorganic nanoparticles, exosomes, and biomimetic vesicles.
Main Results:
- Nanomedicine enhances dopamine stability, BBB transport, controlled release, and targeted delivery to dopaminergic regions.
- Polymeric nanoparticles, lipid-based nanocarriers, and exosome-inspired vesicles show significant promise.
Conclusions:
- Nanotherapeutics offer a viable strategy to overcome limitations of conventional dopaminergic therapies.
- Future directions include AI-assisted design, precision targeting, and stimuli-responsive systems for neurodegenerative disorders.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...